PE20121433A1 - Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1 - Google Patents
Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1Info
- Publication number
- PE20121433A1 PE20121433A1 PE2012000493A PE2012000493A PE20121433A1 PE 20121433 A1 PE20121433 A1 PE 20121433A1 PE 2012000493 A PE2012000493 A PE 2012000493A PE 2012000493 A PE2012000493 A PE 2012000493A PE 20121433 A1 PE20121433 A1 PE 20121433A1
- Authority
- PE
- Peru
- Prior art keywords
- pyridin
- alkyl
- alcoxy
- pyrazolo
- cyclopropyl
- Prior art date
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 102000004500 CCR1 Receptors Human genes 0.000 title 1
- 108010017319 CCR1 Receptors Proteins 0.000 title 1
- 150000005229 pyrazolopyridines Chemical class 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- -1 CARBOXYL Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical group [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 2
- ZYGWIOMAVGEFNH-UHFFFAOYSA-N 3-[1-[[1-(4-fluorophenyl)pyrazolo[3,4-c]pyridine-4-carbonyl]amino]cyclopropyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C2(CC2)NC(=O)C=2C=3C=NN(C=3C=NC=2)C=2C=CC(F)=CC=2)=C1 ZYGWIOMAVGEFNH-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical group O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25359009P | 2009-10-21 | 2009-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121433A1 true PE20121433A1 (es) | 2012-11-10 |
Family
ID=43126891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000493A PE20121433A1 (es) | 2009-10-21 | 2010-10-19 | Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9056858B2 (https=) |
| EP (1) | EP2491028B1 (https=) |
| JP (1) | JP5542946B2 (https=) |
| KR (1) | KR20120087923A (https=) |
| CN (1) | CN102666526A (https=) |
| AP (1) | AP2012006204A0 (https=) |
| AU (1) | AU2010308277A1 (https=) |
| BR (1) | BR112012009331A2 (https=) |
| CA (1) | CA2778060A1 (https=) |
| CL (1) | CL2012000967A1 (https=) |
| CO (1) | CO6531488A2 (https=) |
| DK (1) | DK2491028T3 (https=) |
| EA (1) | EA021015B1 (https=) |
| EC (1) | ECSP12011904A (https=) |
| ES (1) | ES2444780T3 (https=) |
| GE (1) | GEP20146103B (https=) |
| HR (1) | HRP20140213T1 (https=) |
| IL (1) | IL218823A0 (https=) |
| IN (1) | IN2012DN03449A (https=) |
| MA (1) | MA33675B1 (https=) |
| MX (1) | MX2012004644A (https=) |
| NZ (1) | NZ599132A (https=) |
| PE (1) | PE20121433A1 (https=) |
| PH (1) | PH12012500775A1 (https=) |
| PL (1) | PL2491028T3 (https=) |
| PT (1) | PT2491028E (https=) |
| RS (1) | RS53130B (https=) |
| SI (1) | SI2491028T1 (https=) |
| TN (1) | TN2012000180A1 (https=) |
| WO (1) | WO2011049917A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2722923C (en) | 2008-04-29 | 2016-08-02 | Boehringer Ingelheim International Gmbh | Indazole compounds as ccr1 receptor antagonists |
| JP5411927B2 (ja) | 2008-05-06 | 2014-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１アンタゴニストとしてのピラゾール化合物 |
| EP2346868B1 (en) | 2008-09-26 | 2016-01-27 | Boehringer Ingelheim International Gmbh | Azaindazole compounds as ccr1 receptor antagonists |
| EP2491028B1 (en) | 2009-10-21 | 2013-12-11 | Boehringer Ingelheim International GmbH | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
| EP2493875B1 (en) | 2009-10-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Heterocyclic compounds as ccr1 receptor antagonists |
| WO2011137109A1 (en) | 2010-04-30 | 2011-11-03 | Boehringer Ingelheim International Gmbh | Azaindazole amide compounds as ccr1 receptor antagonists |
| EP2655371B1 (en) | 2010-12-23 | 2015-02-25 | Boehringer Ingelheim International GmbH | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
| CA2852160A1 (en) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| KR102410076B1 (ko) | 2014-04-14 | 2022-06-22 | 베링거 인겔하임 인터내셔날 게엠베하 | Ror 감마의 조절제로서의 화합물 |
| CN112707831A (zh) * | 2021-02-05 | 2021-04-27 | 阿里生物新材料（常州）有限公司 | 一种3-（1-氨基环丙基）苯甲酸甲酯的合成方法 |
| WO2025248032A1 (en) | 2024-05-31 | 2025-12-04 | Syngenta Crop Protection Ag | Pesticidally active indazole compounds |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1338625C (en) | 1988-06-09 | 1996-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
| US5242931A (en) | 1988-06-09 | 1993-09-07 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds as TXA2 antagonists |
| US5750542A (en) | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
| WO1992017475A1 (en) | 1991-03-28 | 1992-10-15 | Pfizer Inc. | Heterocyclic-cyclic amine derivatives |
| US5612360A (en) | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| US5616537A (en) | 1992-07-03 | 1997-04-01 | Kumiai Chemical Industry Co., Ltd. | Condensed heterocyclic derivatives and herbicides |
| WO1995000509A1 (en) | 1993-06-25 | 1995-01-05 | Kumiai Chemical Industry Co., Ltd. | Indazolesulfonylurea derivative, use thereof, and intermediate for production thereof |
| WO1996017842A1 (en) | 1994-12-06 | 1996-06-13 | Merck Sharp & Dohme Limited | Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists |
| GB9519563D0 (en) | 1995-09-26 | 1995-11-29 | Merck Sharp & Dohme | Therapeutic agents |
| GB9523583D0 (en) | 1995-11-17 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| EP0939757A1 (en) | 1995-12-22 | 1999-09-08 | Dupont Pharmaceuticals Company | Novel integrin receptor antagonists |
| JPH101478A (ja) | 1996-06-11 | 1998-01-06 | Kumiai Chem Ind Co Ltd | インダゾールスルホニル尿素誘導体及び除草剤 |
| GB9615449D0 (en) | 1996-07-23 | 1996-09-04 | Merck Sharp & Dohme | Therapeutic agents |
| WO1999023076A1 (en) | 1997-11-04 | 1999-05-14 | Pfizer Products Inc. | Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors |
| US6331640B1 (en) | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| EP1192135A2 (en) | 1999-06-14 | 2002-04-03 | Eli Lilly And Company | Serine protease inhibitors |
| DE60022508T2 (de) | 1999-06-14 | 2006-06-08 | Eli Lilly And Co., Indianapolis | Inhibitoren von serin proteasen |
| WO2001000656A2 (en) | 1999-06-29 | 2001-01-04 | Ortho-Mcneil Pharmaceutical, Inc. | Novel indazole peptidomimetics as thrombin receptor antagonists |
| ES2329754T3 (es) | 2000-03-02 | 2009-12-01 | Ndc Infrared Engineering Limited | Aparato de deteccion electromagnetica. |
| GB0030305D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030306D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030303D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030304D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US20050009876A1 (en) | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| US7211594B2 (en) | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
| US7058826B2 (en) | 2000-09-27 | 2006-06-06 | Amphus, Inc. | System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment |
| US20020052373A1 (en) | 2000-10-26 | 2002-05-02 | Zorn Stevin H. | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease |
| AU2002363250A1 (en) | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| WO2008011131A2 (en) | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
| ES2343787T3 (es) | 2002-04-11 | 2010-08-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Derivados de amidas heterociclicas de utilizacion como inhibidores de citoquina. |
| CA2482838A1 (en) | 2002-05-31 | 2003-12-11 | Eisai Co., Ltd. | Pyrazole compounds and pharmaceutical compositions containing the compound |
| DK1531822T3 (da) | 2002-06-12 | 2009-12-07 | Chemocentryx Inc | 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser |
| WO2004014905A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
| TW200500341A (en) | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0203825D0 (sv) | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
| JP2007502307A (ja) | 2003-08-15 | 2007-02-08 | アストラゼネカ アクチボラグ | グルタミン酸ラセマーゼ（ｍｕｒｉ）の阻害剤としての縮合複素環 |
| EP1855670A4 (en) | 2005-02-24 | 2010-05-05 | Merck Sharp & Dohme | BENZAZOLE AMPLIFIERS OF METABOTROPIC GLUTAMATE RECEPTORS |
| GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| DK2444079T3 (en) | 2005-05-17 | 2017-01-30 | Sarcode Bioscience Inc | Compositions and Methods for the Treatment of Eye Diseases |
| US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| BRPI0612112A8 (pt) * | 2005-06-22 | 2017-12-26 | Chemocentryx Inc | composto, composição farmacêutica, e, método de tratar doenças ou condições mediadas por ccr1. |
| BRPI0615048A2 (pt) | 2005-09-01 | 2010-03-30 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
| US20080262040A1 (en) | 2005-10-25 | 2008-10-23 | Smithkline Beecham Corporation | Chemical Compounds |
| MX2009007661A (es) | 2007-01-19 | 2009-12-14 | Ardea Biosciences Inc | Inhibidores de mek. |
| JP2010531344A (ja) | 2007-06-26 | 2010-09-24 | アストラゼネカ アクチボラグ | カテプシンｋ阻害剤としての１−シアノシクロプロピル誘導体 |
| CA2696725A1 (en) | 2007-08-10 | 2009-03-26 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
| MY151004A (en) | 2007-11-29 | 2014-03-31 | Boehringer Ingelheim Int | Derivatives of 6,7-dihydro-5h-imidazo[1,2-?]imidazole-3-carboxylic acid amides |
| CA2722923C (en) | 2008-04-29 | 2016-08-02 | Boehringer Ingelheim International Gmbh | Indazole compounds as ccr1 receptor antagonists |
| JP5411927B2 (ja) | 2008-05-06 | 2014-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１アンタゴニストとしてのピラゾール化合物 |
| EP2346868B1 (en) | 2008-09-26 | 2016-01-27 | Boehringer Ingelheim International Gmbh | Azaindazole compounds as ccr1 receptor antagonists |
| EP2491028B1 (en) | 2009-10-21 | 2013-12-11 | Boehringer Ingelheim International GmbH | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
| EP2493875B1 (en) | 2009-10-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Heterocyclic compounds as ccr1 receptor antagonists |
| CA2782384A1 (en) | 2009-12-08 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds |
| WO2011137109A1 (en) | 2010-04-30 | 2011-11-03 | Boehringer Ingelheim International Gmbh | Azaindazole amide compounds as ccr1 receptor antagonists |
| EP2655371B1 (en) | 2010-12-23 | 2015-02-25 | Boehringer Ingelheim International GmbH | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
-
2010
- 2010-10-19 EP EP10768356.7A patent/EP2491028B1/en active Active
- 2010-10-19 MX MX2012004644A patent/MX2012004644A/es active IP Right Grant
- 2010-10-19 PL PL10768356T patent/PL2491028T3/pl unknown
- 2010-10-19 CN CN2010800578454A patent/CN102666526A/zh active Pending
- 2010-10-19 KR KR1020127010143A patent/KR20120087923A/ko not_active Withdrawn
- 2010-10-19 DK DK10768356.7T patent/DK2491028T3/da active
- 2010-10-19 JP JP2012535292A patent/JP5542946B2/ja active Active
- 2010-10-19 AP AP2012006204A patent/AP2012006204A0/xx unknown
- 2010-10-19 PH PH1/2012/500775A patent/PH12012500775A1/en unknown
- 2010-10-19 BR BR112012009331A patent/BR112012009331A2/pt not_active IP Right Cessation
- 2010-10-19 RS RS20140024A patent/RS53130B/sr unknown
- 2010-10-19 EA EA201200602A patent/EA021015B1/ru not_active IP Right Cessation
- 2010-10-19 GE GEAP201012715A patent/GEP20146103B/en unknown
- 2010-10-19 US US13/499,939 patent/US9056858B2/en active Active
- 2010-10-19 NZ NZ599132A patent/NZ599132A/en not_active IP Right Cessation
- 2010-10-19 PE PE2012000493A patent/PE20121433A1/es not_active Application Discontinuation
- 2010-10-19 PT PT107683567T patent/PT2491028E/pt unknown
- 2010-10-19 CA CA2778060A patent/CA2778060A1/en not_active Abandoned
- 2010-10-19 HR HRP20140213AT patent/HRP20140213T1/hr unknown
- 2010-10-19 SI SI201030538T patent/SI2491028T1/sl unknown
- 2010-10-19 IN IN3449DEN2012 patent/IN2012DN03449A/en unknown
- 2010-10-19 ES ES10768356.7T patent/ES2444780T3/es active Active
- 2010-10-19 AU AU2010308277A patent/AU2010308277A1/en not_active Abandoned
- 2010-10-19 WO PCT/US2010/053142 patent/WO2011049917A1/en not_active Ceased
-
2012
- 2012-03-25 IL IL218823A patent/IL218823A0/en unknown
- 2012-04-16 MA MA34779A patent/MA33675B1/fr unknown
- 2012-04-16 CL CL2012000967A patent/CL2012000967A1/es unknown
- 2012-04-19 TN TNP2012000180A patent/TN2012000180A1/en unknown
- 2012-04-26 CO CO12068976A patent/CO6531488A2/es active IP Right Grant
- 2012-05-16 EC ECSP12011904 patent/ECSP12011904A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2491028T3 (da) | 2014-01-13 |
| PH12012500775A1 (en) | 2012-11-26 |
| MX2012004644A (es) | 2012-05-08 |
| EA201200602A1 (ru) | 2012-12-28 |
| CL2012000967A1 (es) | 2012-09-14 |
| WO2011049917A1 (en) | 2011-04-28 |
| EP2491028A1 (en) | 2012-08-29 |
| JP2013508376A (ja) | 2013-03-07 |
| AU2010308277A1 (en) | 2012-04-26 |
| AP2012006204A0 (en) | 2012-04-30 |
| US20120270870A1 (en) | 2012-10-25 |
| ES2444780T3 (es) | 2014-02-26 |
| IN2012DN03449A (https=) | 2015-10-23 |
| TN2012000180A1 (en) | 2013-12-12 |
| EA021015B1 (ru) | 2015-03-31 |
| ECSP12011904A (es) | 2012-10-30 |
| CA2778060A1 (en) | 2011-04-28 |
| RS53130B (sr) | 2014-06-30 |
| SI2491028T1 (sl) | 2014-03-31 |
| PL2491028T3 (pl) | 2014-05-30 |
| HRP20140213T1 (hr) | 2014-04-11 |
| EP2491028B1 (en) | 2013-12-11 |
| GEP20146103B (en) | 2014-05-27 |
| PT2491028E (pt) | 2014-02-04 |
| JP5542946B2 (ja) | 2014-07-09 |
| IL218823A0 (en) | 2012-06-28 |
| CN102666526A (zh) | 2012-09-12 |
| BR112012009331A2 (pt) | 2019-09-24 |
| KR20120087923A (ko) | 2012-08-07 |
| MA33675B1 (fr) | 2012-10-01 |
| US9056858B2 (en) | 2015-06-16 |
| CO6531488A2 (es) | 2012-09-28 |
| NZ599132A (en) | 2014-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121433A1 (es) | Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1 | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| EA201190142A1 (ru) | Производные пиразола, используемые в качестве антагонистов рецептора ccr4 | |
| BRPI1014902A2 (pt) | composto antagonista de p2x7r, sua composição e seus usos | |
| EA201791271A1 (ru) | ТИАЗОЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, И РОДСТВЕННЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ОРФАННОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ | |
| EA201391662A1 (ru) | Соединения с активностью антагонистов мускариновых рецепторов и агонистов адренергического рецептора бета2 | |
| EA201391584A1 (ru) | Новое соединение, предназначенное для лечения дегенеративных и воспалительных заболеваний | |
| UA112317C2 (uk) | Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину | |
| EA201101709A1 (ru) | Полициклические антагонисты рецепторов лизофосфатидной кислоты | |
| EA202191498A1 (ru) | 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение | |
| PE20151727A1 (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c | |
| PE20141582A1 (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
| UA104489C2 (uk) | Сполуки для лікування дисліпідемії та споріднених хвороб | |
| PH12014502040A1 (en) | Heterocyclyl compounds | |
| DE602006009773D1 (de) | Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen | |
| UA107353C2 (en) | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof | |
| EA201590873A1 (ru) | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов | |
| EA201290394A1 (ru) | Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7 | |
| AR070018A1 (es) | 5-(4-bromo-fenil)-6-[2-(5-bromo-pirimidin-2-iloxi)-etoxi]-pirimidin-4-il sulfamida, composiciones farmaceuticas que lo contienen, metodo de preparacion y uso del mismo en enfermedades asociadas al aumento de la vasoconstriccion, proliferacion o inflamacion debidas a endotelina, tales como insuficien | |
| MX2015013328A (es) | Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartilago. | |
| CL2015002202A1 (es) | Benzamidas sustituidas con actividad hacia receptores ep4. | |
| EA200700027A1 (ru) | Антагонисты рецептора глюкагона, их получение и терапевтическое применение | |
| ATE459619T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| BR112015012842A2 (pt) | diazol lactamas | |
| BRPI0907220A2 (pt) | métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |